Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DX71CK
|
|||
| Drug Name |
QR1123
|
|||
| Synonyms |
ION357
Click to Show/Hide
|
|||
| Drug Type |
Antisense oligonucleotide
|
|||
| Indication | Retinitis pigmentosa [ICD-11: 9B70; ICD-10: H35.5] | Phase 1/2 | [1] | |
| Company |
ProQR Therapeutics Leiden, Netherlands Ionis Pharmaceuticals Carlsbad, CA
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Rhodopsin P23H mutant messenger RNA (RHO P23H mRNA) | Target Info | . | [1] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04123626) A Prospective First-In-Human Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa (adRP) Due to the P23H Mutation in the RHO Gene. U.S.National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.